Related Experiment Video
Updated: May 26, 2026
08:27
Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
Published on: March 24, 2015
RHAMM and CD44 peptides-analytic tools and potential drugs
1London Regional Cancer Center, University of Western Ontario, London, ON, Canada N6A 4L6.
Frontiers in Bioscience (Landmark Edition)
|December 29, 2011
Summary
CD44 and RHAMM are key receptors binding hyaluronan (HA). Peptide therapeutics targeting these receptors show promise for treating diseases like arthritis and cancer by blocking their functions.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- CD44 and RHAMM are cell surface receptors binding hyaluronan (HA).
- Aberrant regulation of CD44 and RHAMM is implicated in diseases such as arthritis and cancer.
- These receptors play crucial roles in wound repair processes.
Purpose of the Study:
- To review the structure and function of CD44 and RHAMM.
- To explore the mechanisms underlying their functions and interactions.
- To summarize the development and application of peptide-based therapeutics targeting CD44 and RHAMM.
Main Methods:
- Literature review of scientific publications.
- Analysis of protein structures and interaction mechanisms.
- Evaluation of experimental data on peptide therapeutics.
Main Results:
- Detailed review of CD44 and RHAMM structures and functions.
- Elucidation of their interaction mechanisms.
- Summary of peptide mimic development for blocking receptor functions.
Conclusions:
- CD44 and RHAMM are critical targets for therapeutic intervention.
- Peptide-based strategies show potential in preclinical models for disease treatment.
- Further research into these receptors and their inhibitors is warranted.
